Changes in plasma levels of vasoactive peptides during sequential bicarbonate hemodialysis.
The hemodynamic response to isolated ultrafiltration (IUF) is characterized by a vasoconstriction, while there is no significant change in peripheral vascular resistance during isovolemic bicarbonate hemodialysis (IVHD). The present investigation was designed to study the plasma levels of vasoactive regulatory peptides together with noradrenaline (NA) and plasma renin activity (PRA) in 11 patients during sequential hemodialysis (SQHD) - IUF for 60 min, followed by IVHD for 210 min. During IUF, the vasoconstrictors arginine vasopressin (AVP), gamma 2-melanocyte-stimulating hormone (gamma 2-MSH), neuropeptide Y (NPY), NA and PRA increased. During IVHD, NPY and PRA remained unchanged on a higher level. A decrease in AVP below the baseline and in gamma 2-MSH and NA to the baseline levels occurred during IVHD. In the case of vasodilators, there were no changes in calcitonin gene-related peptide or motilin during SQHD. An increase in beta-endorphin (beta-END) occurred during IUF, followed by a decrease during IVHD. Substance P and vasoactive intestinal peptide were unchanged during IUF but decreased during IVHD. We conclude that SQHD is characterized by an increase in all the measured vasoconstrictors during IUF in response to loss of fluid, and by a decrease in some vasoconstrictors (AVP, gamma 2-MSH, NA) during IVHD. With the exception of beta-END, there were no changes or only minor ones in vasodilators during SQHD. There are changes in plasma levels of vasoactive substances during SQHD but the importance of these changes for the hemodynamic adaptation to ultrafiltration and dialysis needs to be studied further.
Hegbrant
J
J
Department of Nephrology, University Hospital, Lund, Sweden.
Thysell
H
H
Mårtensson
L
L
Ekman
R
R
Boberg
U
U
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001127:Arginine Vasopressin / Q000097:blood; D001639:Bicarbonates; D005260:Female; D006439:Hemodynamics; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000503:physiopathology / Q000628:therapy; D008297:Male; D009074:Melanocyte-Stimulating Hormones / Q000097:blood; D008875:Middle Aged; D009478:Neuropeptide Y / Q000097:blood; D009479:Neuropeptides / Q000097:blood*; D009638:Norepinephrine / Q000097:blood; D006435:Renal Dialysis / Q000009:adverse effects / Q000379:methods*; D012083:Renin / Q000097:blood; D014462:Ultrafiltration; D001615:beta-Endorphin / Q000097:blood
D001639:Bicarbonates; D009478:Neuropeptide Y; D009479:Neuropeptides; D001127:Arginine Vasopressin; D001615:beta-Endorphin; D009074:Melanocyte-Stimulating Hormones; D012083:Renin; D009638:Norepinephrine